PRGS&Tech, a South Korean biotech company, advanced to the final round of XPRIZE Healthspan's $110 million competition with Progerinin, a drug originally developed for progeria that targets progerin, an abnormal protein accelerating cellular aging. The company is one of ten finalists worldwide testing whether a therapy designed for rare genetic aging diseases can slow aging broadly in people aged 50–90 within a single year of treatment.
Key Points
- Progerinin targets progerin protein, which accelerates cellular aging in rare genetic diseases
- PRGS&Tech is South Korea's only remaining finalist among ten global teams in competition
- Trial aims to reverse ten years of aging within one year; $81 million prize available for maximum su
Longevity Analysis
The translation of therapies from rare accelerated-aging diseases to the broader aging population represents a direct approach to decoding why normal aging occurs. Progerin's role in cellular aging is well-characterized, making it a specific target rather than a systemic guess. If Progerinin successfully demonstrates measurable restoration of muscle function, cognitive performance, and immune competence in otherwise healthy older adults within twelve months, it provides concrete evidence that a single molecular intervention can produce measurable, clinically meaningful changes in aging rate—a long-standing open question in longevity science.
Original published by Longevity.Technology, by Kyle Umipig.